Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RegenMatrix-PRP-XLHA for Moderate to Severe Knee Osteoarthritis
NCT05727371Active, not recruiting
- Sponsor
- RegenLab
- Start
- Aug 2023
- Primary completion
- Feb 2026
- Modality
- Adipose-derived MSCs, Hydrogel Systems, Bone Marrow MSCs
- Countries
- 1
01
Overview
Randomised, double-blind trial of platelet-rich plasma and hyaluronic acid hydrogel in knee osteoarthritis (OA) (3 arms), sponsored by RegenLab. Primary endpoint: Variation in the osteoarthritis related pain at 6 months. Started Aug 2023; status: active, not recruiting.
02
Drugs
platelet-rich plasmahyaluronic acid hydrogel
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05727371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727371.